What is Cortagen 20MG

Cortagen 20MG is a synthetic tetrapeptide bioregulator studied in research for its profound neuroprotective effects and ability to stimulate nerve tissue regeneration. It is intended exclusively for research use.

Regarding its chemical identity, Cortagen has a molecular formula of C17H26N4O9 and a molecular weight of 430.41 g/mol. Its reported canonical sequence is Ala-Glu-Asp-Pro. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Cortagen.

Product for research use.

Mechanism of action of Cortagen

Cortagen interacts with the DNA of neurons to regulate the expression of proteins like Interleukin-2 and various neurotrophic factors. It decreases apoptosis in brain cells under stress and enhances structural and functional recovery in the central and peripheral nervous systems.

Pharmacokinetics and pharmacodynamics of Cortagen

Like other short cytogens, Cortagen has a rapid onset of action and an extremely short plasma half-life. Its biological impact is measured by the sustained upregulation of neurotrophic factors long after the peptide is degraded.

Scientific evidence on Cortagen

The available evidence on Cortagen is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Investigated in preclinical models of nerve crush injuries, ischemic stroke, and neurodegenerative conditions. Evidence suggests it accelerates the restoration of nerve conduction velocity and reduces the extent of ischemic damage in brain tissue.

Cortagen applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Cortagen protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Cortagen, so no trial schemes or quantities are specified.

The presentations of this product (20MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Cortagen

As a general guideline for laboratory handling, lyophilized peptides such as Cortagen are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 20MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Cortagen Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Cortagen security profile

The documented safety information in open sources for Cortagen is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Given its action on the central nervous system, theoretical concerns might include overstimulation of specific neural pathways, but preclinical models have not reported significant toxicological profiles. Unverified for human safety.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Cortagen in a comparative context

Belonging to the same family as Pinealon, Cortagen is derived from cortex extracts. Compared to general neurotropics like Semax, Cortagen operates more directly at the genetic level to stimulate foundational nerve repair rather than immediate cognitive enhancement.

History and development of Cortagen

Developed as a synthetic counterpart to Cortexin (a complex extract of animal brain tissue). Cortagen was isolated and synthesized by Russian researchers to provide a more targeted, stable molecule for studying neuroregeneration.